Squarepoint Ops LLC Lowers Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Squarepoint Ops LLC decreased its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 38.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 384,132 shares of the biopharmaceutical company's stock after selling 242,051 shares during the quarter. Squarepoint Ops LLC owned about 0.07% of Royalty Pharma worth $9,799,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Allworth Financial LP lifted its position in shares of Royalty Pharma by 417.6% in the fourth quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 877 shares in the last quarter. Riverview Trust Co raised its position in Royalty Pharma by 3,953.3% during the fourth quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company's stock worth $31,000 after acquiring an additional 1,186 shares in the last quarter. Fifth Third Bancorp lifted its stake in shares of Royalty Pharma by 187.1% during the 4th quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company's stock worth $39,000 after buying an additional 997 shares during the last quarter. Rakuten Securities Inc. lifted its stake in shares of Royalty Pharma by 160.5% during the 4th quarter. Rakuten Securities Inc. now owns 1,628 shares of the biopharmaceutical company's stock worth $42,000 after buying an additional 1,003 shares during the last quarter. Finally, Blue Trust Inc. lifted its stake in shares of Royalty Pharma by 31.3% during the 4th quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 376 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on RPRX. Morgan Stanley initiated coverage on shares of Royalty Pharma in a research note on Friday, May 16th. They set an "overweight" rating and a $51.00 price objective on the stock. Citigroup restated a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th. Finally, Wall Street Zen cut shares of Royalty Pharma from a "buy" rating to a "hold" rating in a research report on Tuesday, May 20th. Two investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $42.50.

Royalty Pharma Trading Down 0.2%

Shares of RPRX traded down $0.07 during mid-day trading on Thursday, reaching $32.56. The company's stock had a trading volume of 700,457 shares, compared to its average volume of 3,462,269. The company's fifty day moving average price is $32.34 and its two-hundred day moving average price is $30.29. Royalty Pharma plc has a 52 week low of $24.05 and a 52 week high of $34.32. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64. The stock has a market cap of $18.77 billion, a PE ratio of 22.45, a P/E/G ratio of 2.31 and a beta of 0.49.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.99 by $0.07. The company had revenue of $839.00 million for the quarter, compared to the consensus estimate of $724.69 million. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. On average, analysts predict that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be paid a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 2.70%. The ex-dividend date is Friday, May 16th. Royalty Pharma's dividend payout ratio (DPR) is presently 47.57%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.